(Q37207581)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18602438%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

review article

1 reference

title

Prospects for use of interleukin-12 as a mucosal adjuvant for vaccination of humans to protect against respiratory pneumococcal infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18602438%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18602438%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Siamon Gordon

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18602438%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

A K A Wright

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18602438%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

D E Briles

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18602438%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

language of work or name

English

0 references

publication date

3 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18602438%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

number of pages

11

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18602438%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18602438%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

4893-4903

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18602438%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18602438%20AND%20SRC:MED&resulttype=core&format=json

Pulmonary defences to acute respiratory infection.

10 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Mucosal immunity and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Targeting the innate immune response with improved vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Protective effect of antibiotics against serious complications of common respiratory tract infections: retrospective cohort study with the UK General Practice Research Database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Pneumococcal vaccination in developing countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Bacteremia among children admitted to a rural hospital in Kenya.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Poor potential coverage for 7-valent pneumococcal conjugate vaccine, Malawi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Streptococcus pneumoniae colonisation: the key to pneumococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Vaccine adjuvants revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

The relevance of cytokines for development of protective immunity and rational design of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Influence of DNA encoding cytokines on systemic and mucosal immunity following genetic vaccination against herpes simplex virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Interleukin-12 promotes gamma interferon-dependent neutrophil recruitment in the lung and improves protection against respiratory Streptococcus pneumoniae infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Interleukin-12 and the regulation of innate resistance and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Direct binding of IL-12 to human and murine B lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

What kind of message does IL-12/IL-23 bring to macrophages and dendritic cells?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Development, cytokine profile and function of human interleukin 17-producing helper T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

How microorganisms tip the balance between interleukin-12 family members

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Interleukin-17 family and IL-17 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Molecular characterization of the human interleukin (IL)-17 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Regulatory T cells and infection: a dangerous necessity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

IL-12 is a potent neonatal vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

IL-10 or not IL-10: that is the question

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

The Brighton Collaboration: enhancing comparability of vaccine safety data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Negligible adjuvant effect for antibody responses and frequent adverse events associated with IL-12 treatment in humans vaccinated with pneumococcal polysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

The innate immune response to pneumococcal lung infection: the untold story.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

An important role for polymeric Ig receptor-mediated transport of IgA in protection against Streptococcus pneumoniae nasopharyngeal carriage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Host and bacterial factors contributing to the clearance of colonization by Streptococcus pneumoniae in a murine model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

IL-18 improves the early antimicrobial host response to pneumococcal pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Interleukin 12 deficiency associated with recurrent infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Essential role for the p40 subunit of interleukin-12 in neutrophil-mediated early host defense against pulmonary infection with Streptococcus pneumoniae: involvement of interferon-gamma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Inhaled cytokines and cytokine antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Inhaled vs oral steroids for adults with chronic asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Low CD4 T cell immunity to pneumolysin is associated with nasopharyngeal carriage of pneumococci in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this “adaptive response” in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/microL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Interleukin-12 in the treatment of chronic hepatitis B and C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058

Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.058